Medirom Healthcare Technologies Inc (MRM) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Medirom Healthcare Technologies Inc stock (MRM) is currently trading at $1.13. Medirom Healthcare Technologies Inc PE ratio is 3.30. Medirom Healthcare Technologies Inc PS ratio (Price-to-Sales) is 0.00. Analyst consensus price target for MRM is $5.12. WallStSmart rates MRM as Sell.
- MRM PE ratio analysis and historical PE chart
- MRM PS ratio (Price-to-Sales) history and trend
- MRM intrinsic value — DCF, Graham Number, EPV models
- MRM stock price prediction 2025 2026 2027 2028 2029 2030
- MRM fair value vs current price
- MRM insider transactions and insider buying
- Is MRM undervalued or overvalued?
- Medirom Healthcare Technologies Inc financial analysis — revenue, earnings, cash flow
- MRM Piotroski F-Score and Altman Z-Score
- MRM analyst price target and Smart Rating
Medirom Healthcare Technologies Inc
📊 No data available
Try selecting a different time range
MRM Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Medirom Healthcare Technologies Inc (MRM)
MRM trades at a significant discount to its Graham intrinsic value of $17.32, offering a 92% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Medirom Healthcare Technologies Inc (MRM) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, price/sales, eps growth. Concerns around market cap and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Medirom Healthcare Technologies Inc (MRM) Key Strengths (3)
Every $100 of shareholder equity generates $53 in profit
Paying less than $1 for every $1 of annual revenue
Strong earnings growth at 27.80% per year
Supporting Valuation Data
Medirom Healthcare Technologies Inc (MRM) Areas to Watch (6)
Losing money on operations
Revenue declining -6.70%, a shrinking business
Very expensive at 6.3x book value
Very thin margins, barely profitable
Very low institutional interest at 0.23%
Micro-cap company with very limited liquidity and high volatility
Medirom Healthcare Technologies Inc (MRM) Detailed Analysis Report
Overall Assessment
This company scores 39/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 3 register as strengths (avg 9.3/10) while 6 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Price/Sales, EPS Growth. Valuation metrics including Price/Sales (0.00) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 53.20%. Growth metrics are encouraging with EPS Growth at 27.80%.
The Bear Case
The primary concerns are Operating Margin, Revenue Growth, Price/Book. Some valuation metrics including Price/Book (6.29) suggest expensive pricing. Growth concerns include Revenue Growth at -6.70%, which may limit upside. Profitability pressure is visible in Operating Margin at -25.80%, Profit Margin at 0.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 53.20% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at -6.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
MRM Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
MRM's Price-to-Sales ratio of 0.00x trades at a deep discount to its historical average of 0.01x (6th percentile). The current valuation is 96% below its historical high of 0.03x set in Jan 2021, and Infinity% above its historical low of 0x in Mar 2025. Over the past 12 months, the PS ratio has expanded from ~0.0x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Medirom Healthcare Technologies Inc (MRM) · CONSUMER CYCLICAL › PERSONAL SERVICES
The Big Picture
Medirom Healthcare Technologies Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 8.1B with 7% decline year-over-year. Profit margins are thin at 0.5%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
ROE of 53.2% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Revenue contracted 7% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Margin expansion: can Medirom Healthcare Technologies Inc push profit margins above 15% as the business scales?
Debt management: total debt of 27M is significantly higher than cash (226,127). Monitor refinancing risk.
Sector dynamics: monitor PERSONAL SERVICES industry trends, competitive moves, and regulatory changes that could impact Medirom Healthcare Technologies Inc.
Bottom Line
Medirom Healthcare Technologies Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 12:56:12 PM
About Medirom Healthcare Technologies Inc(MRM)
NASDAQ
CONSUMER CYCLICAL
PERSONAL SERVICES
USA
MEDIROM Healthcare Technologies Inc. provides comprehensive healthcare services in Japan. The company is headquartered in Tokyo, Japan.